Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hyper… Read more
Verve Therapeutics Inc (VERV) - Net Assets
Latest net assets as of March 2025: $473.51 Million USD
Based on the latest financial reports, Verve Therapeutics Inc (VERV) has net assets worth $473.51 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($614.16 Million) and total liabilities ($140.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $473.51 Million |
| % of Total Assets | 77.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.67 |
Verve Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Verve Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Verve Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Verve Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $493.40 Million | -17.70% |
| 2023-12-31 | $599.50 Million | +8.82% |
| 2022-12-31 | $550.93 Million | +54.17% |
| 2021-12-31 | $357.35 Million | +659.16% |
| 2020-12-31 | $-63.91 Million | -226.85% |
| 2019-12-31 | $-19.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verve Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72218200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $89.00K | 0.02% |
| Other Comprehensive Income | $428.00K | 0.09% |
| Other Components | $1.24 Billion | 250.49% |
| Total Equity | $493.40 Million | 100.00% |
Verve Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Verve Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ãlker Bisküvi Sanayi A.S.
F:A7G
|
$727.78 Million |
|
CLEAR CHANNEL O.H.A DL-01
F:C7C1
|
$728.13 Million |
|
Ratos AB ser. B
LSE:0KBQ
|
$728.14 Million |
|
Shenzhen Farben Information Technology Co.Ltd.
SHE:300925
|
$728.40 Million |
|
Greatek Electronics Inc
TW:2441
|
$727.39 Million |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
$727.30 Million |
|
Sichuan Yimikang Environmental Tech Co Ltd
SHE:300249
|
$727.27 Million |
|
Suzhou Oriental Semiconductor Co. Ltd. A
SHG:688261
|
$727.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verve Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 599,502,000 to 493,400,000, a change of -106,102,000 (-17.7%).
- Net loss of 198,709,000 reduced equity.
- New share issuances of 46,734,000 increased equity.
- Other comprehensive income increased equity by 156,000.
- Other factors increased equity by 45,717,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-198.71 Million | -40.27% |
| Share Issuances | $46.73 Million | +9.47% |
| Other Comprehensive Income | $156.00K | +0.03% |
| Other Changes | $45.72 Million | +9.27% |
| Total Change | $- | -17.70% |
Book Value vs Market Value Analysis
This analysis compares Verve Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.41 | $11.13 | x |
| 2020-12-31 | $-1.33 | $11.13 | x |
| 2021-12-31 | $7.37 | $11.13 | x |
| 2022-12-31 | $10.20 | $11.13 | x |
| 2023-12-31 | $9.34 | $11.13 | x |
| 2024-12-31 | $5.82 | $11.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verve Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -614.59%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.31x
- Recent ROE (-40.27%) is below the historical average (-22.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.06 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.15 Million |
| 2021 | -33.20% | 0.00% | 0.00x | 1.07x | $-154.37 Million |
| 2022 | -28.57% | -8108.55% | 0.00x | 1.23x | $-212.48 Million |
| 2023 | -33.37% | -1701.55% | 0.02x | 1.26x | $-260.02 Million |
| 2024 | -40.27% | -614.59% | 0.05x | 1.31x | $-248.05 Million |
Industry Comparison
This section compares Verve Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verve Therapeutics Inc (VERV) | $473.51 Million | 0.00% | 0.30x | $727.51 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |